|
The Mission of NovImmune as a drug development company is to develop new therapeutic agents in the field of immune-related disorders and inflammation. This includes autoimmune diseases and immunosuppression in organ transplantation.
NovImmune's applied research relies on internationally recognized scientific excellence in molecular and cellular immuno-biology.
Commitment to fully human therapeutic monoclonal antibodies allows NovImmune to move rapidly from the choice of medically relevant targets to the introduction of new therapeutic agents into clinical trials. NovImmune has already demonstrated its ability to deliver its own products into clinical trials in a short time period.
NovImmune is the owner of totally novel targets that play a key role in the control of the immune response. These fully validated targets are used by NovImmune for the development of novel classes of low molecular weight inhibitors as anti-inflammatory and immunosuppression agents.
|
